PR3-ANCA Vasculitis: Diagnosis, Management, and Follow-Up
Diagnosis
In patients with clinical features compatible with small-vessel vasculitis and positive PR3-ANCA serology, start immunosuppressive therapy immediately without waiting for kidney biopsy results, especially if the patient is rapidly deteriorating 1.
Diagnostic Approach
- Serologic testing: Use high-quality antigen-specific immunoassays for PR3-ANCA as the preferred screening method 1
- Clinical presentation: Look for upper/lower respiratory tract involvement, pauci-immune necrotizing crescentic glomerulonephritis, microscopic hematuria with dysmorphic RBCs and red cell casts, moderate proteinuria (1-3 g/day), and rapidly declining GFR over days to weeks 1
- Biopsy strategy:
- If PR3-ANCA positive with compatible clinical picture and low suspicion for secondary vasculitis at an experienced center with rapidly progressive disease → commence treatment immediately, biopsy soon after starting treatment 1
- Biopsy provides prognostic information but should not delay therapy in deteriorating patients 1
Critical pitfall: About 10% of patients with small-vessel vasculitis are ANCA-negative, so negative serology does not exclude the diagnosis 1.
Management
Induction Therapy (New-Onset Disease)
Use glucocorticoids combined with either rituximab OR cyclophosphamide for remission induction 1 (Grade 1B recommendation).
Choosing Between Rituximab vs. Cyclophosphamide:
Cyclophosphamide is preferred when:
- Severe glomerulonephritis with serum creatinine >4 mg/dL (>354 μmol/L) 1
- Consider combining rituximab with 2 IV pulses of cyclophosphamide in this severe setting 1
Rituximab is preferred when:
Specific Dosing Regimens:
Rituximab: 375 mg/m²/week × 4 weeks 1
IV Cyclophosphamide: 15 mg/kg at weeks 0,2,4,7,10,13
- Reduce to 12.5 mg/kg if age >60 years
- Reduce to 10 mg/kg if age >70 years
- Reduce by 2.5 mg/kg if GFR <30 mL/min/1.73 m² 1
Oral Cyclophosphamide: 2 mg/kg/day for 3 months (maximum 6 months)
- Reduce to 1.5 mg/kg/day if age >60 years
- Reduce to 1.0 mg/kg/day if age >70 years
- Reduce by 0.5 mg/kg/day if GFR <30 mL/min/1.73 m² 1
Glucocorticoids: Use lower-dose, rapidly tapering regimens (safer and equally effective as standard-dose) 2
Avacopan: 30 mg twice daily can be used as alternative to glucocorticoids in combination with rituximab or cyclophosphamide 1
Adjunctive Therapies:
Plasma exchange: Consider for:
- Serum creatinine >3.4 mg/dL (>300 μmol/L) 1
- Dialysis-dependent patients
- Rapidly increasing creatinine
- Diffuse alveolar hemorrhage with hypoxemia 1
Note: Recent evidence suggests plasma exchange provides no additional benefit for most patients with severe AAV, though still used case-by-case 2.
Maintenance Therapy
After achieving remission, use either rituximab OR azathioprine with low-dose glucocorticoids for maintenance 1 (Grade 1C recommendation).
Duration: 18 months to 4 years after induction of remission 1
Rituximab is strongly preferred for PR3-ANCA patients due to higher relapse risk 3, 2.
Rituximab Maintenance Dosing (choose one protocol):
- MAINRITSAN scheme: 500 mg × 2 at complete remission, then 500 mg at months 6,12, and 18 1
- RITAZAREM scheme: 1000 mg after remission induction, then at months 4,8,12, and 16 1
Azathioprine Maintenance Dosing:
- Start 1.5-2 mg/kg/day at complete remission
- Continue until 1 year after diagnosis, then decrease by 25 mg every 3 months
- For extended therapy: Continue at 1.5-2 mg/kg/day for 18-24 months, then decrease to 1 mg/kg/day until 4 years after diagnosis, then taper by 25 mg every 3 months 1
Glucocorticoids: Continue at 5-7.5 mg/day for 2 years, then slowly reduce by 1 mg every 2 months 1
Alternative Maintenance Agents:
- Mycophenolate mofetil: 2000 mg/day (divided doses) for 2 years if azathioprine intolerant 1
- Methotrexate: Only if GFR ≥60 mL/min/1.73 m² and azathioprine intolerant 1
Relapsing Disease
Patients with relapse should be re-induced with the same regimen as new-onset disease, preferably with rituximab 1.
PR3-ANCA patients have significantly higher relapse risk compared to MPO-ANCA patients 3, 4. Consider longer maintenance duration (toward 4 years) for PR3-positive patients 2.
Refractory Disease
Treatment options 1:
- Increase glucocorticoids (IV or oral)
- Add rituximab if cyclophosphamide was used initially, or vice versa
- Consider plasma exchange
Follow-Up and Monitoring
ANCA Monitoring
Persistence of PR3-ANCA positivity, rising ANCA levels, or conversion from negative to positive predicts future relapse and should guide treatment decisions 1.
Key monitoring principles 3:
- Structured clinical assessment should inform treatment decisions, not ANCA or CD19+ B-cell testing alone (Grade 1B)
- However, ANCA and B-cell status are highly predictive of relapses in rituximab-treated patients 4
Specific predictive patterns 4:
- Patients achieving and maintaining PR3-ANCA negativity: 3% relapse rate
- Persistent PR3-ANCA positivity: 37% relapse rate (P=0.002)
- Reappearance of PR3-ANCAs: 50% relapse rate (P=0.002)
- 96% of relapses in PR3-ANCA patients occurred with persistent or reappearing PR3-ANCAs
B-Cell Monitoring (for rituximab-treated patients)
- Incomplete B-cell depletion: 54% relapse rate vs. 26% with depletion (P=0.02) 4
- B-cell repopulation: 41% relapse rate vs. 15% without repopulation (P=0.03) 4
- Measure serum immunoglobulin concentrations prior to each rituximab course to detect secondary immunodeficiency 3
Infection Prophylaxis
Use trimethoprim-sulfamethoxazole prophylaxis against Pneumocystis jirovecii pneumonia for patients receiving rituximab, cyclophosphamide, and/or high-dose glucocorticoids 3 (Grade 1B).
Comorbidity Screening
- Urinalysis periodically for all cyclophosphamide-treated patients (bladder cancer risk) 3
- Screen for cardiovascular risk factors (diabetes, hypertension)
- Monitor for osteoporosis and chronic kidney disease 3
Center of Care
Patients with AAV should be treated at centers with experience in AAV management 1, 3.
Critical Clinical Pearls
PR3-ANCA positivity is the single strongest predictor of relapse - these patients need rituximab maintenance and longer treatment duration 3, 2, 4
Absence of PR3-ANCA is highly predictive of remaining relapse-free - 96% of patients who achieved and maintained PR3-ANCA negativity remained relapse-free 4
Don't delay treatment for biopsy in rapidly deteriorating patients with positive PR3-ANCA and compatible clinical picture 1
Severe renal disease (Cr >4 mg/dL) requires cyclophosphamide or combination rituximab + cyclophosphamide, as rituximab alone has limited data in this setting 1
Dual MPO/PR3 positivity occurs in rare cases (~50% develop AAV, either drug-induced or idiopathic) and requires individualized assessment 5